ライフサイエンスコーパス: multicentre trial

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 phase III, double-blind, placebo-controlled, multicentre trial.

2 randomised, placebo-controlled, double-blind multicentre trial.

3 ve, randomized, blinded, placebo controlled, multicentre trial.

4 lic hepatitis pending the results from large multicentre trials.

5 d, controlled, double-blind, parallel-group, multicentre trial (11 sites in Finland, Germany, the Net

6 rdised care can also facilitate planning for multicentre trials and help with the identification of a

7 Multicentre trials are needed to show whether vitamin su

8 We did a randomised, phase 2, open-label, multicentre trial at 37 centres in five countries and en

9 randomised double-blind, placebo-controlled, multicentre trial at three sites in Delhi (urban), Pune

10 Multicentre trials contradicted the benefits of tight co

11 The FAME study was a multicentre trial done in Belgium, Denmark, Germany, the

12 ctive-controlled, open-label, international, multicentre trial, done at 106 sites across nine countri

13 A multicentre trial evaluated the dose-response and tolera

14 The MRC Multicentre trial for Early Epilepsy and Single Seizures

15 We did a randomised, open-label multicentre trial in 59 hospitals--57 in the UK, one in

16 We did a randomised, double-blinded, multicentre trial in adults (n=586) with diabetes and a

17 2, randomised, parallel-group, double-blind multicentre trial in patients with New York Heart Associ

18 stic factors in this rare disease and assist multicentred trials in the evaluation of different treat

19 iated with poor functional outcomes; a large multicentre trial is currently comparing it against barb

20 adical prostate radiotherapy in the MRC RT01 multicentre trial (ISRCTN47772397, n=224) or in the Conv

21 In two placebo-controlled, double-blind, multicentre trials (M2-124 and M2-125) with identical de

22 We did a randomised multicentre trial of 1810 patients with non-ST-elevation

23 Multicentre trials of vitamin D supplementation for prev

24 In this phase 2b, double-blind, multicentre trial, patients (aged 18-75 years) with, or

25 In this open-label, phase 1, multicentre trial, single subcutaneous injections of rAv

26 ernational, open-label, randomised, phase 3, multicentre trial (TH CR-406/SARC021) at 81 academic or

27 REAL07 was an open-label, multicentre trial that was done in 13 centres in Italy a

28 ng cooperation and collaboration to complete multicentre trials that advance knowledge and patient ca

29 We did a multicentre trial to compare the outcomes of patients tr

30 We undertook a randomised, multicentre trial to compare the safety and efficacy of

31 We undertook a randomised, multicentre trial to compare these treatments in patient

32 We undertook a randomised multicentre trial to compare these two approaches.

33 We did a randomised multicentre trial to resolve this issue.

34 We did a randomised multicentre trial to try to resolve this issue.

35 QUEST-1, a phase 3, randomised, double-blind multicentre trial undertaken in 13 countries (Australia,

36 This open-label randomised controlled multicentre trial was part of a larger study.

37 ernational, open-label, randomised, phase 3, multicentre trial, we enrolled adult patients with CD30-

38 this pragmatic, randomised, parallel-group, multicentre trial, we recruited adults with symptoms sug

39 For this open-labelled, multicentre trial, we recruited patients aged 18 years o

40 In this UK-based multicentre trial, we used an independent central random

41 ion and treatment has improved, high-quality multicentre trials with long-term follow-up are needed.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。